Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Neurological Disorder Drugs Market From 2025 To 2029?

The market for drugs aimed at neurological disorders has witnessed significant expansion in the recent past. There is expected to be a growth from $84.6 billion in 2024 to about $90.09 billion in 2025. This growth rate, calculated annually, will compound to about 6.5%. This historical progress can be traced back to a rise in animal testing yielding hopeful results, the climb of therapeutic cures, the expansion of neurological issues, governmental drives, and an increase in spending in the healthcare sector.

What Is the Projected Market Size of the Neurological Disorder Drugs Market?

The market size for drugs related to neurological conditions is poised for robust growth in the coming years, expanding to $114.65 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. The projected growth in the forecast period is largely due to the rise in customized therapy options, an increased concentration on treatments that modify diseases, the wider application of digital biomarkers, and the growing incidence of neurological conditions. The anticipated trends in this forecast period comprise advancements in the designing of drugs, improvements in neuroimaging, progressed genetic research, increased collaborations and licensing agreements, along with the advent of regenerative medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Who are the Major Competitors in the Neurological Disorder Drugs Market Outlook?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What Is Fueling Growth in the Neurological Disorder Drugs Market?

The growth of the neurological disorder drugs market is anticipated to be fueled by the rising prevalence of neurological diseases. These disorders are conditions that impact the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, and they trigger varied symptoms. The uptick in the instances of such diseases is owed to an aging global populace and heightened exposure to environmental, metabolic, and lifestyle-related risk factors. Neurological disorder drugs are crucial in managing these complicated illnesses – they provide symptom relief, slow the disease evolution, and enhance patients’ long-term outcomes. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in September 2024 that it is forecasted there will be a significant surge in dementia cases in Australia from 2023 to 2058. The count will likely more than double from roughly 411,100 in 2023 to 849,300 by 2058, affecting around 315,500 men and 533,800 women. Therefore, the upward trend of neurological disease prevalence fuels the expansion of the neurological disorder drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Neurological Disorder Drugs Market Segments Are Growing the Fastest?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Which Industry Trends Are Shaping the Future of the Neurological Disorder Drugs Market?

Leading firms in the neurological disorder drugs market are concentrating on the advancement of novel Ocrelizumab drug therapies to heighten treatment effectiveness, optimize patient results, and broaden treatment choices for people suffering from multiple sclerosis. Serving as a therapeutic drug in treating multiple sclerosis (MS), a form of neurological disorder, Ocrelizumab is a humanized monoclonal antibody. For instance, February 2024 saw the launch of Ocrevus (Ocrelizumab), a fresh disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis, by Roche Holding AG, a Swiss-based pharmaceutical company, in India. Backed by more than a decade of clinical and real-world data, Ocrevus is the inaugural and solitary approved DMT for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Ocrevus, a monoclonal antibody, targets CD20-positive B cells, which are conjectured to contribute to the autoimmune assault on the central nervous system in multiple sclerosis. It is applicable in treating both RRMS and PPMS, thereby being the first-ever approved drug for both these variants of the disease. Intravenously administered typically every six months, Ocrevus has manifested effectiveness in curbing disease activity and mitigating disability progression in clinical trials.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Countries Are Leading the Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

This Report Delivers Insight On:

1. How big is the neurological disorder drugs market, and how is it changing globally?

2. Who are the major companies in the neurological disorder drugs market, and how are they performing?

3. What are the key opportunities and risks in the neurological disorder drugs market right now?

4. Which products or customer segments are growing the most in the neurological disorder drugs market?

5. What factors are helping or slowing down the growth of the neurological disorder drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model